Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure
Standard
Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure. / Lautenbach, Anne; Kantowski, Tobias; Wagner, Jonas; Mann, Oliver; Stoll, Fabian; Aberle, Jens.
In: CLIN OBES, Vol. 13, No. 5, 10.2023, p. e12593.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure
AU - Lautenbach, Anne
AU - Kantowski, Tobias
AU - Wagner, Jonas
AU - Mann, Oliver
AU - Stoll, Fabian
AU - Aberle, Jens
N1 - © 2023 The Authors. Clinical Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
PY - 2023/10
Y1 - 2023/10
N2 - About 20%-25% of patients experience weight regain (WR) or insufficient weight loss (IWL) following bariatric surgery (BS). Therefore, we aimed to retrospectively assess the effectiveness of adjunct treatment with semaglutide in patients without type 2 diabetes (T2D) with post-bariatric treatment failure over a 12 months period. Post-bariatric patients without T2D with WR or IWL (n = 29) were included in the analysis. The primary endpoint was weight loss 12 months after initiation of adjunct treatment. Secondary endpoints included change in body mass index, HbA1c, lipid profile, high sensitive C-reactive protein and liver enzymes. Total weight loss during semaglutide treatment added up to 14.7% ± 8.9% (mean ± SD, p < .001) after 12 months. Categorical weight loss was >5% in 89.7% of patients, >10% in 62.1% of patients, >15% in 34.5% of patients, >20% in 24.1% of patients and > 25% in 17.2% of patients. Adjunct treatment with semaglutide resulted in sustained weight loss regardless of sex, WR or IWL and type of surgery. Among patients with prediabetes (n = 6), 12 months treatment led to normoglycemia in all patients (p < .05). Treatment options to manage post-bariatric treatment failure are scarce. Our results imply a clear benefit of adjunct treatment with semaglutide in post-bariatric patients over a 12 months follow-up period.
AB - About 20%-25% of patients experience weight regain (WR) or insufficient weight loss (IWL) following bariatric surgery (BS). Therefore, we aimed to retrospectively assess the effectiveness of adjunct treatment with semaglutide in patients without type 2 diabetes (T2D) with post-bariatric treatment failure over a 12 months period. Post-bariatric patients without T2D with WR or IWL (n = 29) were included in the analysis. The primary endpoint was weight loss 12 months after initiation of adjunct treatment. Secondary endpoints included change in body mass index, HbA1c, lipid profile, high sensitive C-reactive protein and liver enzymes. Total weight loss during semaglutide treatment added up to 14.7% ± 8.9% (mean ± SD, p < .001) after 12 months. Categorical weight loss was >5% in 89.7% of patients, >10% in 62.1% of patients, >15% in 34.5% of patients, >20% in 24.1% of patients and > 25% in 17.2% of patients. Adjunct treatment with semaglutide resulted in sustained weight loss regardless of sex, WR or IWL and type of surgery. Among patients with prediabetes (n = 6), 12 months treatment led to normoglycemia in all patients (p < .05). Treatment options to manage post-bariatric treatment failure are scarce. Our results imply a clear benefit of adjunct treatment with semaglutide in post-bariatric patients over a 12 months follow-up period.
KW - Humans
KW - Diabetes Mellitus, Type 2/drug therapy
KW - Hypoglycemic Agents/therapeutic use
KW - Retrospective Studies
KW - Weight Loss
KW - Bariatrics
KW - Treatment Failure
U2 - 10.1111/cob.12593
DO - 10.1111/cob.12593
M3 - SCORING: Journal article
C2 - 37364260
VL - 13
SP - e12593
JO - CLIN OBES
JF - CLIN OBES
SN - 1758-8103
IS - 5
ER -
